Industry
Industry — US Managed Healthcare
US managed care organizations (MCOs) take a fixed per-member-per-month (PMPM) premium and assume the risk that actual medical costs come in below that rate. The industry sells one product — financial risk on someone else's healthcare — across three regulated sub-markets (Medicaid, Medicare Advantage, ACA Marketplace), each with its own buyer, pricing cycle, and contract length. Molina is the pure-play government-program specialist: 75% of premium revenue is state Medicaid, with the rest in Medicare and Marketplace. The first number every investor watches is the medical care ratio (MCR) — medical costs divided by premium revenue — because a 100–200 basis-point swing can cut net income in half, as Molina demonstrated in 2025.
1. Industry in One Page
The newcomer's misconception. Managed care looks like an insurance company. It is closer to a state-regulated, government-contracted utility: the customer is usually a state Medicaid agency or CMS — not the patient — and the price is set by an actuarial rate book, not by what the market will bear. The leverage point for profitability is medical-cost control, not premium pricing power.
2. How This Industry Makes Money
Revenue is a stream of fixed PMPM premiums set by state Medicaid agencies (Medicaid), CMS (Medicare Advantage), and approved actuarial rate filings (Marketplace). Cost is whatever the doctors, hospitals, pharmacies, and drugs actually consume — a number the MCO does not fully control. Scale matters mostly for fixed-cost absorption (admin, technology, regulatory compliance), not for premium-side leverage.
Capital intensity is low, but regulatory capital requirements at each state-licensed subsidiary tie up substantial equity. The economics favor operators who can pull medical costs down a few percentage points faster than the rate book moves up.
3. Demand, Supply, and the Cycle
Demand is set by program eligibility, not consumer choice. Medicaid grows when economies weaken or eligibility expands (the ACA Medicaid expansion added roughly 21 million covered lives nationally). Medicare grows with the aging of the population — Medicare Advantage penetration of the Medicare-eligible pool climbed past 50% in 2024. Marketplace is the most volatile: enrollment swings on subsidy policy and the size of the uninsured pool.
The cycle is a rate-versus-trend cycle: medical costs (utilization × unit price) rise continuously, and rates re-price on a lag. Margins compress when actuaries underestimate next year's cost trend (the 2024-25 episode in Medicaid), then snap back as the rate book catches up.
A 250bps consolidated MCR move can halve net income: operating margin fell from 4.2% to 1.7% and ROE from 27% to 11% in FY2025.
4. Competitive Structure
The US managed care industry is moderately concentrated nationally but locally fragmented. Three vertically integrated giants (UnitedHealth, CVS Health/Aetna, Elevance Health) hold roughly 60% of the publicly traded premium pool. Two pure-play government specialists (Centene, Molina) compete head-to-head in Medicaid and Marketplace. Humana is the largest pure-play in Medicare Advantage. State-by-state competition is what actually matters — most contracts are awarded by state agencies to 3-6 plans per region.
State-level concentration drives bid economics. In any given Medicaid procurement, the field typically narrows to 4-6 plans, and the state awards 2-4 contracts. Incumbency helps but does not protect: Molina lost its Virginia Medicaid contract effective June 2025 despite legal protest.
5. Regulation, Technology, and Rules of the Game
This is the most regulation-sensitive sub-industry in the S&P 500. Profit pools can be reshaped by a single CMS rate notice or a single piece of federal legislation. The 2025-2027 calendar is unusually dense.
OBBBA is the big one. Molina explicitly estimates a 15-20% reduction in its 1.2 million Medicaid Expansion members between 2027 and 2029. The expansion population tends to be lower-acuity than the residual Medicaid pool, so revenue loss is compounded by a worse risk mix on what remains.
Technology shifts that actually matter to industry economics in 2026 are narrower than the headlines suggest. AI-assisted utilization management, claims adjudication, and prior-authorization automation are reducing G&A ratios by 20-50bps per year at the larger operators. GLP-1 drug uptake is a cost trend driver, not a benefit, because Medicaid generally must cover them. Telehealth is mostly margin-neutral — it shifted setting more than spend.
6. The Metrics Professionals Watch
If you only watch two, watch MCR and the adjusted G&A ratio — together they capture roughly 99% of the variance in MCO net income.
7. Where Molina Healthcare Fits
The structural question for MOH inside the industry. Pure-play Medicaid is structurally lower-margin than vertically integrated managed care because there is no PBM rebate spread, no care-delivery margin, and minimum-loss-ratio rules cap upside. Investors are paid for that risk through scale-driven ROIC: even at the FY2025 trough, MOH delivered roughly 13% ROIC. The bull case rests on rates catching up to trend in 2026-27; the bear case is that OBBBA shrinks the addressable population and the catch-up never comes.
8. What to Watch First
These seven signals are observable within a single news cycle and together tell you whether the rate-versus-trend cycle that defined 2024-25 is bending back in favor of pure-play Medicaid operators.